Nova Eye Medical Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Tom Spurling

Chief executive officer

AU$291.1k

Total compensation

CEO salary percentage84.3%
CEO tenure4.3yrs
CEO ownership0.4%
Management average tenure6.3yrs
Board average tenure6.4yrs

Recent management updates

Recent updates

We Think Nova Eye Medical (ASX:EYE) Can Afford To Drive Business Growth

Nov 04
We Think Nova Eye Medical (ASX:EYE) Can Afford To Drive Business Growth

Nova Eye Medical Limited (ASX:EYE) Might Not Be As Mispriced As It Looks After Plunging 26%

Sep 22
Nova Eye Medical Limited (ASX:EYE) Might Not Be As Mispriced As It Looks After Plunging 26%

Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)

Aug 06
Take Care Before Diving Into The Deep End On Nova Eye Medical Limited (ASX:EYE)

Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward

Apr 18
Nova Eye Medical Limited (ASX:EYE) Soars 29% But It's A Story Of Risk Vs Reward

Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?

Mar 26
Is There An Opportunity With Nova Eye Medical Limited's (ASX:EYE) 43% Undervaluation?

News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts

Jan 19
News Flash: Analysts Just Made A Captivating Upgrade To Their Nova Eye Medical Limited (ASX:EYE) Forecasts

Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce

Dec 27
Further Upside For Nova Eye Medical Limited (ASX:EYE) Shares Could Introduce Price Risks After 38% Bounce

We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate

Sep 03
We're Not Very Worried About Nova Eye Medical's (ASX:EYE) Cash Burn Rate

Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified

Apr 17
Improved Revenues Required Before Nova Eye Medical Limited (ASX:EYE) Stock's 43% Jump Looks Justified

Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?

Dec 16
Is Nova Eye Medical (ASX:EYE) In A Good Position To Invest In Growth?

We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully

Aug 27
We Think Nova Eye Medical (ASX:EYE) Needs To Drive Business Growth Carefully

CEO Compensation Analysis

How has Tom Spurling's remuneration changed compared to Nova Eye Medical's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$291kAU$245k

-AU$9m

Mar 31 2024n/an/a

-AU$12m

Dec 31 2023n/an/a

-AU$14m

Sep 30 2023n/an/a

-AU$15m

Jun 30 2023AU$253kAU$211k

-AU$15m

Mar 31 2023n/an/a

-AU$13m

Dec 31 2022n/an/a

-AU$11m

Sep 30 2022n/an/a

-AU$9m

Jun 30 2022AU$311kAU$191k

-AU$7m

Mar 31 2022n/an/a

-AU$7m

Dec 31 2021n/an/a

-AU$6m

Sep 30 2021n/an/a

-AU$5m

Jun 30 2021AU$72kAU$66k

-AU$4m

Dec 31 2020n/an/a

-AU$9m

Sep 30 2020n/an/a

-AU$10m

Jun 30 2020n/an/a

-AU$10m

Dec 31 2019n/an/a

-AU$6m

Sep 30 2019n/an/a

-AU$6m

Jun 30 2019AU$328kAU$306k

-AU$7m

Mar 31 2019n/an/a

-AU$7m

Dec 31 2018n/an/a

-AU$6m

Sep 30 2018n/an/a

-AU$6m

Jun 30 2018AU$329kAU$300k

-AU$5m

Compensation vs Market: Tom's total compensation ($USD181.11K) is below average for companies of similar size in the Australian market ($USD288.99K).

Compensation vs Earnings: Tom's compensation has increased whilst the company is unprofitable.


CEO

Tom Spurling (62 yo)

4.3yrs

Tenure

AU$291,117

Compensation

Mr. Thomas H. Spurling, also known as Tom, BSc (Hons), Ph D., FRACI, FTSE, AM is an Executive Director at Nova Eye Medical Limited since August 31, 2020 and serves as its Managing Director. Mr. Spurling wa...


Leadership Team

NamePositionTenureCompensationOwnership
Victor Previn
Founder & Executive Chairman23.4yrsAU$254.51kno data
Thomas Spurling
MD & Executive Directorno dataAU$291.12k0.37%
A$ 126.8k
Kimberley Menzies
Chief Financial Officerno datano datano data
Mark Flynn
Investor Relationsno datano datano data
Kate Hunt
Chief Commercial Officerno datano datano data
David Lubeck
Chief Medical Officer6.2yrsno datano data
Joaquin Wolff
President of Ellex iTrack6.4yrsno datano data
Simon Jeremy Gray
Company Secretary4.5yrsno datano data
Don Watton
Vice President of Global Serviceno dataAU$143.97kno data
Meera Verma
Advisor to the Boardno dataAU$243.97kno data

6.3yrs

Average Tenure

66yo

Average Age

Experienced Management: EYE's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Victor Previn
Founder & Executive Chairman23.4yrsAU$254.51kno data
Thomas Spurling
MD & Executive Director4.3yrsAU$291.12k0.37%
A$ 126.8k
Rahmon Coupe
Independent Director11.6yrsAU$55.50k0.59%
A$ 201.2k
Michael Southard
Non Executive Director6.4yrsAU$61.05k0.0087%
A$ 3.0k
Daniel Webb
Independent Director2.1yrsAU$61.05k0.24%
A$ 83.3k

6.4yrs

Average Tenure

62yo

Average Age

Experienced Board: EYE's board of directors are considered experienced (6.4 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/27 08:23
End of Day Share Price 2024/12/27 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Nova Eye Medical Limited is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Tanushree JainBell Potter
Michael YouldenMST Financial Services Pty Limited
Robin MorganTaylor Collison Limited